Katherine G. Tarlock, MD
Cancer and Blood Disorders Center
On staff since September 2014
Academic Title: Assistant Professor
Research Center: Center for Clinical and Translational Research
"The privilege of caring for patients and families during challenging medical diagnoses is what drew me to this field and continues to be the best part of my job. I am dedicated to advancing our understanding of leukemia and being able to offer every child and family the best care."
-
-
Dr. Tarlock is the best doctor I have met so far in the 18 years I have lived in Seattle. She is highly knowledgeable, very smart, very responsible, trustworthy and also a very caring person. She gave the best treatment to my son suffering from Leukemia at every stage of his treatment. I will be ever grateful to her for saving his life and giving our family a new beginning.
-
A wonderful provider! She took care of our 4 year old son when he was very ill on the Hem/Onc floor. We really loved her approach to treating kids. We greatly appreciated her knowledge, care, and compassion.
-
-
Award Name Award Description Awarded By Award Date Alberta Corkery Fellowship Travel Award American Society of Hematology Abstract Achievement Award Outstanding Pediatric Resident Award Lucile Packard Children's Hospital Outstanding Presentation Award Seattle Children's Hospital Fellow Research Day Alpha Omega Alpha Medical Honor Society Pediatric Clerkship Award Chicago Medical School -
Other Publications
-
Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis AS, Meshinchi SGemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
26644412 Clinical cancer research : an official journal of the American Association for Cancer Research, 2016 April 15 : 22(8)1951-7 PMCID:PMC4834220 -
Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis AS, Meshinchi SGemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
26644412 Clinical cancer research : an official journal of the American Association for Cancer Research, 2015 Dec. 7 -
Tarlock K, Chang B, Cooper T, Gross T, Gupta S, Neudorf S, Adlard K, Ho PA, McGoldrick S, Watt T, Templeman T, Sisler I, Garee A, Thomson B, Woolfrey A, Estey E, Meshinchi S, Pollard JASorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
25662999 Pediatric blood and cancer, 2015 June : 62(6)1048-54
-
-
Grant Title Grantor Amount Award Date Targeting Novel Pediatric-Specific FLT3 Mutations Alexs Lemonade Stand Foundation Feb. 1, 2016 - Jan. 31, 2018 Validation of Mesothelin as a Therapeutic Target in Childhood AML Childrens Oncology Group, Integrated Translational Science Center, Hematology Jan. 1, 2016 - June 1, 2016 Novel Therapeutic Strategy Identification in Relapsed FLT3/ITD Acute Myeloid Leukemia Hyundai Hope on Wheels, Young Investigator Award Dec. 31, 2015 - Dec. 31, 2017 Pathway Directed Treatment for Refractory AML Sts Baldricks Foundation, St's Baldrick's Consortium Grant July 1, 2015 - June 30, 2016 Identification of Resistance Mechanisms and Novel Therapeutic Strategies in Tyrosine Kinase Inhibitor Resistant FLT3/ITD Acute Myeloid Leukemia Alexs Lemonade Stand Foundation, ALSF Young Investigator Award July 1, 2014 - June 30, 2016 Biology and Prognostic Implications of FLT3 Mutations in AML National Cancer Institute/National Institutes of Health, R01 CA 114563, Sept. 20, 2012 - July 31, 2017
Overview
- Board Certification(s)
-
Pediatrics
Pediatric Hematology-Oncology
- Medical/Professional School
-
Rosalind Franklin University of Medicine and Science - Chicago Medical School, North Chicago
- Residency
-
Pediatrics, Stanford University Lucile Packard Children's Hospital, Palo Alto
- Fellowship
-
Pediatric Hematology Oncology, Seattle Children's Hospital, Seattle
- Clinical Interests
-
Leukemias, adolescents and young adults
- Research Description
-
Acute myeloid leukemia, chemotherapy resistance, identification of novel therapeutic agents in childhood leukemias
